Adult Immunization Allergy & Immunology Cardiology Dermatology Endocrinology Gastroenterology Infectious Disease Men’s Health Nephrology Neurology Pain Management Pediatric Immunization Pediatrics Psychiatry Pulmonology Rheumatology Screening Women’s Health

Billing and Collections Career Planning Coding and Documentation Concierge Medicine Cybersecurity EHRs Investing Patient Relations Personal Finance Practice Management Remote Patient Monitoring Staffing Technology Telehealth Value-based Care

VMS and Menopause Atopic Dermatitis Provider Toolkit Adult Immunization Provider Toolkit Dermatology Hot Topics

Interstitial lung disease

>

Latest News

FDA Approves Nerandomilast, First New IPF Treatment in More Than a Decade / image credit ©Waldennarus/stock.adobe.com

FDA Approves Nerandomilast, First New IPF Treatment in More Than a Decade

By Grace Halsey

October 8th 2025

Approval of the novel oral PDE4B inhibitor offers hope to individuals with the rare, chronic, and progressive pulmonary disease for which treatment options are few.

The IPF Pipeline image credit IPF ©Vector Market/stock.adobe.com (AI)

The IPF Pipeline is Set to Deliver: The 3 Top Contenders

By Grace Halsey

September 10th 2025

© Michael_Vi/stock.adboe.com

Nerandomilast Meets Primary Endpoint in Phase III FIBRONEER-ILD Trial in Progressive Pulmonary Fibrosis

By Grace Halsey

February 11th 2025

Editorial Board

Terms and Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2025 MJH Life Sciences

All rights reserved.